Abstract
The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Current Pharmaceutical Design
Title: Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Volume: 14 Issue: 4
Author(s): Cecil S. Thompson
Affiliation:
Keywords: Diabetes mellitus, animal models, microvascular complications, macrovascular complications
Abstract: The prevalence of diabetes mellitus is increasing worldwide at an alarming rate due to population growth, obesity, sedentary lifestyle and aging. Consequently, diabetic microvascular complications (retinopathy and nephropathy) and macrovascular complications (coronary heart disease, peripheral arterial disease and cerebrovascular disease) are also rising. Traditional oral hypoglycaemic agents only partially prevent the development of these complications. This suggests that selective treatment options that target specific biological pathways (i.e. metabolic factors, intracellular signaling proteins and growth factors) may be a more effective strategy. Type 1 and Type 2 diabetic animal models have been produced spontaneously by selective inbreeding or by genetic modification, as well as, pharmacological induction. These models have become a safe and reliable option to test the therapeutic potential of novel drugs. They also help to understand the pathophysiology of diabetes mellitus. This review highlights the most commonly used animal models for the treatment of diabetic micro and macrovascular complications.
Export Options
About this article
Cite this article as:
Thompson S. Cecil, Animal Models of Diabetes Mellitus: Relevance to Vascular Complications, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497679
DOI https://dx.doi.org/10.2174/138161208783497679 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Context-Dependency of Relations Between Cardiovascular Phenotypes and Genes Involved in Sodium Homeostasis: Findings from the European Project on Genes in Hypertension
Current Hypertension Reviews Rosuvastatin and Diabetes: When the Evidences Talk
Cardiovascular & Hematological Agents in Medicinal Chemistry Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Infections and Atheromatous Plaque: Current Therapeutic Implications
Current Pharmaceutical Design Graphical Abstracts:
Current Cardiology Reviews The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Current Vascular Pharmacology Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study
Current Drug Targets Targeting FoxO1 for Hypertriglyceridemia
Current Drug Targets A Review of Gene Expression Profiling of Human Embryonic Stem Cell Lines and their Differentiated Progeny
Current Stem Cell Research & Therapy Diadenosine Polyphosphates: Postulated Mechanisms Mediating the Cardiac Effects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery The Impact of Methodology and Confounding Variables on the Association Between Major Depression and Coronary Heart Disease: Review and Recommendations
Current Psychiatry Reviews Magnesium Lithospermate B Extracted from Salvia Miltiorrhiza, A Potential Substitute for Cardiac Glycosides
Mini-Reviews in Organic Chemistry Inflammation, Sleep, Obesity and Cardiovascular Disease.
Current Vascular Pharmacology Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine
CNS & Neurological Disorders - Drug Targets Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Novel Drugs Targeting the c-Ring of the F<sub>1</sub>F<sub>O</sub>-ATP Synthase
Mini-Reviews in Medicinal Chemistry